Earning Analysis
Welcome to our in-depth analysis of Novartis AG(NVS) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of Novartis AG earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.
Earnings Forecast
Revenue
EPS
Currency: USD
Actual
Estimate
Surprise Analysis
| FY2025Q3 | 2025-10-28 | Pre-Market | 2.26 | - | - | 13.87B | 13.91B | +0.31 | -4.42 | -4.14 |
| FY2025Q2 | 2025-07-17 | Pre-Market | 2.38 | 2.42 | +1.68 | 14.06B | 14.05B | -0.06 | -3.25 | -1.30 |
| FY2025Q1 | 2025-04-29 | - | 2.12 | - | - | 13.05B | 13.23B | +1.40 | +0.73 | +1.47 |
| FY2024Q4 | 2025-01-31 | Pre-Market | 1.81 | 1.98 | +9.39 | 12.82B | 13.15B | +2.57 | -0.03 | +2.13 |
| FY2024Q3 | 2024-10-29 | Pre-Market | 1.94 | 2.06 | +6.19 | 12.67B | 12.82B | +1.24 | -4.41 | -4.42 |
| FY2024Q2 | 2024-07-18 | - | 1.87 | 1.97 | +5.35 | 12.32B | 12.51B | +1.57 | -4.10 | -2.25 |
| FY2024Q1 | 2024-04-23 | - | 1.73 | 1.80 | +4.05 | 11.50B | 11.83B | +2.88 | +2.27 | +2.07 |
| FY2023Q4 | 2024-01-31 | - | 1.64 | 1.53 | -6.71 | 11.77B | 11.42B | -2.97 | -3.97 | -3.72 |
| FY2023Q3 | 2023-10-24 | - | 1.70 | 1.74 | +2.35 | 11.37B | 11.78B | +3.60 | +0.23 | -0.98 |
| FY2023Q2 | 2023-07-18 | - | 1.68 | 1.83 | +8.93 | 13.27B | 13.62B | +2.65 | +4.57 | +5.21 |
NVS Earnings Analysis
Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, Novartis AG reported performance for FY2025Q3, announced on 2025-10-28. The company achieved an EPS of , compared to analyst estimates of 2.26 by % . Revenue for the quarter reached 13.91B compared to expectations of 13.87B by 0.31% .
The stock price reacted with a -4.42% one-day change and a -4.14% five-day change following the earnings release. These movements reflect market reaction in Novartis AG growth trajectory and strategic initiatives.
NVS Earnings Forecast
Looking ahead, Novartis AG(NVS) remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2025/Q4 project quarter revenue of 13.64B and an EPS of 1.93.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been Revise Upward by 0.71%, while EPS estimates have been Revise Upward by 0.39%. For the upcoming Q4 2025, revenue estimates have been adjusted Revise Upward by 0.37% . These revisions correlate with a 2.08% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in Novartis AG long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
Estimate Revision
The chart shows the correlation between NVS's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2025
Revise Upward
+0.71%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+0.39%
In Past 3 Month
Revenue Estimates for Q4 2025
Revise Upward
+0.37%
In Past 3 Month
Stock Price
Go Up
+2.08%
In Past 3 Month
1Y
3Y
5Y
Annual FY 2025
Currency: USD
1Y
3Y
5Y
--
Revenue Estimate-Annual FY 2025:55.49B
--
EPS Estimate-Annual FY 2025:8.96
—
Stock Price132.43
NVS Revenue and EPS Performance: A Historical Perspective
Novartis AG revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
FY2025Q3 (2025-10-28,Pre-Market):
EPS: (Actual) vs.2.26 (Estimate) (%)
Revenue: 13.91B (Actual) vs. 13.87B (Estimate) (0.31%)
Price Reaction: -4.42%(1-Day), -4.14%(5-Day)
FY2025Q2 (2025-07-17,Pre-Market):
EPS: 2.42 (Actual) vs.2.38 (Estimate) (1.68%)
Revenue: 14.05B (Actual) vs. 14.06B (Estimate) (-0.06%)
Price Reaction: -3.25%(1-Day), -1.30%(5-Day)
FY2025Q1 (2025-04-29,):
EPS: (Actual) vs.2.12 (Estimate) (%)
Revenue: 13.23B (Actual) vs. 13.05B (Estimate) (1.40%)
Price Reaction: 0.73%(1-Day), 1.47%(5-Day)
Earnings Reaction
The chart below shows how NVS performed 10 days before and after its earnings report, based on data from the past quarters. Typically, NVS sees a +1.06% change in stock price 10 days leading up to the earnings, and a -0.44% change 10 days following the report. On the earnings day itself, the stock moves by -1.24%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in SEP/2025, the stock changed -1.32% on the day following the earnings release and then changed by 5.73% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
Transcript Summary
Novartis AG (NVS) Q3 2025 Earnings Call Summary
Positive
2025-10-28
The earnings call summary indicates a positive outlook with strong sales growth, strategic product expansions, and a significant share buyback program. Despite some margin pressure from generic competition, Novartis plans to offset it with productivity improvements. The Q&A reveals confidence in product launches and market strategies, with no major negative sentiments from analysts. The upgraded guidance and share buyback plan further support a positive sentiment, suggesting a likely stock price increase of 2% to 8% over the next two weeks.
Novartis AG (NVS) Q2 2025 Earnings Call Summary
Positive
2025-07-20
The earnings call summary shows strong financial performance, innovative product development, and strategic market positioning, with positive guidance on sales and income growth. The Q&A section supports optimism with management's confidence in product growth and strategic initiatives. Shareholder returns are strong with ongoing buybacks. Despite some uncertainties in pricing policies, the overall sentiment is positive, suggesting a likely stock price increase.
Novartis AG (NVS) Q1 2025 Earnings Call Summary
Positive
2025-04-30
The earnings call summary indicates strong financial performance, with impressive EPS growth, increased free cash flow, and upgraded guidance for sales and operating income. The company is committed to shareholder returns via dividends and share buybacks. While there are some concerns about regulatory issues and competitive pressures, management has taken steps to mitigate risks. The Q&A session revealed some uncertainty regarding tariffs and investment timelines, but overall sentiment remains positive with a focus on growth and innovation.
Novartis AG (NVS) Q1 2025 Earnings Call Summary
Positive
2025-04-29
The earnings call presents strong financial performance with increased net sales, core operating income, and margins. The raised sales and income guidance, along with significant shareholder returns via dividends and buybacks, are positive indicators. The Q&A section reveals management's confidence in handling tariffs and competitive pressures, despite some uncertainties regarding tariffs and generic competition. Overall, the positives outweigh the negatives, suggesting a positive stock price movement over the next two weeks.
Novartis AG (NVS) Q2 2024 Earnings Call Summary
Positive
2024-07-18
The earnings call summary reflects strong financial performance with record high revenue growth and robust EPS increase. The shareholder return plan through dividends and buybacks is positive. The Q&A section reveals optimism about product opportunities and market expansion, despite some delays and competitive challenges. Adjustments in ratings are minimal as the core financials and optimistic guidance outweigh concerns. The overall sentiment leans positive, suggesting a likely stock price increase between 2% to 8% over the next two weeks.
People Also Watch
FAQ
What were the key highlights of NVS’s latest earnings report for FY2025Q3?
How did NVS’s stock price react after the FY2025Q3 earnings release?
What are the revenue and EPS estimates for NVS for 2025/Q4?
How does NVS’s stock price correlate with earnings forecast revisions?
What should investors expect from NVS’s next earnings report?